Homology Medicines, Inc. (FIXX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Homology Medicines, Inc. (FIXX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5327
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Homology Medicines, Inc. (Homology Medicines) is a pre-clinical stage biopharmaceutical company engaged in translating gene editing and gene therapy into novel treatment for patients suffering from rare genetic diseases. It offers HMI-102 product, which is in clinical stage for the treatment of Phenylketonuria (PKU). The company’s gene editing technology is used in DNA repairs, and gene therapy approach along with AAVHSC vectors delivers a functional gene to treat monogenic diseases in the liver, lung, none marrow and eye. Genetic medicines are used for treating newborn and pediatric patients. Homology Medicines is headquartered in Bedford, Massachusetts, the US.

Homology Medicines, Inc. (FIXX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Homology Medicines, Inc., Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Homology Medicines Raises USD83.5 Million in Series B Financing 10
Homology Medicines Raises USD43.5 Million in Series A Financing Round 12
Homology Medicines Raises USD23 Million in Venture Financing 14
Partnerships 15
Homology Medicines Enters into Agreement with Novartis 15
Licensing Agreements 16
Homology Medicines Amends its Licensing Agreement with California Institute of Technology 16
City of Hope Signs Licensing Agreement with Homology Medicines 17
Equity Offering 18
Homology Medicines Raises USD165.6 Million in IPO 18
Homology Medicines, Inc. – Key Competitors 20
Homology Medicines, Inc. – Key Employees 21
Homology Medicines, Inc. – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Aug 13, 2018: Homology Medicines reports second quarter 2018 financial results 23
May 14, 2018: Homology Medicines Announces First Quarter 2018 Financial Results 25
Corporate Communications 27
Mar 15, 2018: Homology Medicines Appoints Mary Thistle to Board of Directors 27
Jan 17, 2018: Homology Medicines Appoints Matthew R. Patterson to Board of Directors 28
Apr 04, 2017: Homology Medicines Appoints Brad Smith as Chief Financial Officer 29
Product News 30
Jul 16, 2018: Homology Medicines announces peer-reviewed publication demonstrating efficient and precise in vivo gene editing capabilities of nuclease-free technology platform 30
Mar 01, 2018: Homology Medicines Announces Peer-Reviewed Publication Indicating Low Prevalence of Pre-existing Neutralizing Antibodies to its Human-Derived AAVHSC Vectors 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Key Facts, 2017 2
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Homology Medicines, Inc., Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Homology Medicines, Inc., Deals By Therapy Area, 2012 to YTD 2018 8
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Homology Medicines Raises USD83.5 Million in Series B Financing 10
Homology Medicines Raises USD43.5 Million in Series A Financing Round 12
Homology Medicines Raises USD23 Million in Venture Financing 14
Homology Medicines Enters into Agreement with Novartis 15
Homology Medicines Amends its Licensing Agreement with California Institute of Technology 16
City of Hope Signs Licensing Agreement with Homology Medicines 17
Homology Medicines Raises USD165.6 Million in IPO 18
Homology Medicines, Inc., Key Competitors 20
Homology Medicines, Inc., Key Employees 21

List of Figures
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Homology Medicines, Inc. (FIXX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Abg Sundal Collier Holding Asa
    Abg Sundal Collier Holding Asa - Strategy, SWOT and Corporate Finance Report Summary Abg Sundal Collier Holding Asa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Weis Markets, Inc.:戦略・SWOT・企業財務分析
    Weis Markets, Inc. - Strategy, SWOT and Corporate Finance Report Summary Weis Markets, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development-製薬・医療分野:企業M&A・提携分析
    Summary Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a subsidiary of National Institutes of Health is a research institute that conducts and supports laboratory research, clinical trials, and epidemiological studies. The institute conducts research in the …
  • Taisei Corporation:企業の戦略・SWOT・財務分析
    Taisei Corporation - Strategy, SWOT and Corporate Finance Report Summary Taisei Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Hachsharat Hayishuv Hotels Ltd.:企業の戦略・SWOT・財務分析
    Hachsharat Hayishuv Hotels Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hachsharat Hayishuv Hotels Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Oriental Hotels Ltd:企業の戦略・SWOT・財務分析
    Oriental Hotels Ltd - Strategy, SWOT and Corporate Finance Report Summary Oriental Hotels Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Elavon Inc:企業の戦略・SWOT・財務分析
    Elavon Inc - Strategy, SWOT and Corporate Finance Report Summary Elavon Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Commerce Resources Corp (CCE):企業の財務・戦略的SWOT分析
    Summary Commerce Resources Corp (Commerce Resources) is a minerals exploration and development company that explores for deposits of rare earth elements and rare metals. The company acquires, explores, produces, develops, evaluates mineral resource properties, and others. It explores for niobium and …
  • Formosa Plastics Corp (1301):企業の財務・戦略的SWOT分析
    Formosa Plastics Corp (1301) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Horizon Oil Ltd (HZN):企業の財務・戦略的SWOT分析
    Summary Horizon Oil Ltd (Horizon) is an oil and gas exploration and production company that acquires, explores, develops and produces oil and petroleum properties. The company holds interests in Maari and Manaia fields located in the Taranaki Basin approximately 80 kilometre offshore the north islan …
  • Tien Phong Commercial Joint Stock Bank (TPB):企業の財務・戦略的SWOT分析
    Tien Phong Commercial Joint Stock Bank (TPB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Cidara Therapeutics Inc (CDTX):企業の財務・戦略的SWOT分析
    Summary Cidara Therapeutics Inc (Cidara), formerly K2 Therapeutics Inc is a biotechnology company that discovers, develops and commercializes novel anti-infectives including immunotherapies. The company's pipeline products include CD101 for treatment of invasive fungal disease; and CD377 for treatin …
  • Lund University:製薬・医療:M&Aディール及び事業提携情報
    Summary Lund University (LNU) is an educational service provider that offers master and bachelor programmes. It offers education and research in the areas of engineering, economics and management, science, law, social sciences, medicine, humanities, theology, fine art, music and others. The universi …
  • Indra Sistemas SA (IDR):企業の財務・戦略的SWOT分析
    Indra Sistemas SA (IDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • OncoSec Medical Inc (ONCS)-製薬・医療分野:企業M&A・提携分析
    Summary OncoSec Medical Inc (OncoSec) is a biotechnology company that offers services to stimulate body’s immune system and attack cancer. It’s lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through i …
  • Banca Del Ceresio SA:企業の戦略・SWOT・財務情報
    Banca Del Ceresio SA - Strategy, SWOT and Corporate Finance Report Summary Banca Del Ceresio SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • State Street Corporation:企業のM&A・事業提携・投資動向
    State Street Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's State Street Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Petrolympic Ltd (PCQ):石油・ガス:M&Aディール及び事業提携情報
    Summary Petrolympic Ltd (Petrolympic) is an oil and gas exploration and development company that acquires, explores and develops light crude oil and natural gas in North America. The company holds interests in conventional natural gas and light oil projects in Gaspe Peninsula of Quebec. It holds int …
  • Glavbolgarstroy Holdings AD:企業の戦略・SWOT・財務情報
    Glavbolgarstroy Holdings AD - Strategy, SWOT and Corporate Finance Report Summary Glavbolgarstroy Holdings AD - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Marsh & McLennan Companies Inc:企業の戦略・SWOT・財務分析
    Marsh & McLennan Companies Inc - Strategy, SWOT and Corporate Finance Report Summary Marsh & McLennan Companies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆